{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:44:40Z","timestamp":1769906680325,"version":"3.49.0"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100000801","name":"Bayer Healthcare","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000801","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005614","name":"Biogen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005614","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Genzyme\/Sanofi-Aventis"},{"name":"Merck Serono"},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Almirall"},{"name":"Bayer Health Care"},{"DOI":"10.13039\/100006314","name":"Biogen Idec","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006314","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004329","name":"Genzyme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004329","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Merck Serono"},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004191","name":"Novo Nordisk","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008976","name":"Sanofi-Aventis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008976","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006259","name":"Teva","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100006259","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100005614","name":"Biogen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005614","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010795","name":"Chugai","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010795","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Diamed"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","jns-journal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Neurological Sciences"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1016\/j.jns.2017.03.001","type":"journal-article","created":{"date-parts":[[2017,3,7]],"date-time":"2017-03-07T19:18:27Z","timestamp":1488914307000},"page":"181-190","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"C","title":["Benefit-risk perception of natalizumab therapy in neurologists and a large cohort of multiple sclerosis patients"],"prefix":"10.1016","volume":"376","author":[{"given":"Christoph","family":"Heesen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ingo","family":"Kleiter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sven G.","family":"Meuth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2219-5593","authenticated-orcid":false,"given":"Julia","family":"Kr\u00e4mer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00fcrgen","family":"Kasper","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sascha","family":"K\u00f6pke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wolfgang","family":"Gaissmaier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.jns.2017.03.001_bb0005","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1056\/NEJMoa044397","article-title":"A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis","volume":"354","author":"Polman","year":"2006","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"10.1016\/j.jns.2017.03.001_bb0015","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1007\/s00415-011-6116-8","article-title":"Progressive multifocal leukoencephalopathy and natalizumab","volume":"258","author":"Hellwig","year":"2011","journal-title":"J. Neurol."},{"issue":"3","key":"10.1016\/j.jns.2017.03.001_bb0020","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1002\/ana.22128","article-title":"Anti-JC virus antibodies: implications for PML risk stratification","volume":"68","author":"Gorelik","year":"2010","journal-title":"Ann. Neurol."},{"issue":"20","key":"10.1016\/j.jns.2017.03.001_bb0025","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1056\/NEJMoa1107829","article-title":"Risk of natalizumab-associated progressive multifocal leukoencephalopathy","volume":"366","author":"Bloomgren","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.jns.2017.03.001_bb0030","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1002\/ana.24286","article-title":"Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy","volume":"76","author":"Plavina","year":"2014","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.jns.2017.03.001_bb0035","doi-asserted-by":"crossref","first-page":"361","DOI":"10.2147\/TCRM.S41552","article-title":"Bridging, switching or drug holidays - how to treat a patient who stops natalizumab?","volume":"9","author":"Havla","year":"2013","journal-title":"Ther. Clin. Risk Manag."},{"issue":"17","key":"10.1016\/j.jns.2017.03.001_bb0040","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1212\/WNL.0000000000000355","article-title":"MS disease activity in RESTORE: a randomized 24-week natalizumab treatment interruption study","volume":"82","author":"Fox","year":"2014","journal-title":"Neurology"},{"issue":"10","key":"10.1016\/j.jns.2017.03.001_bb0045","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1002\/acn3.114","article-title":"Outcome and survival of asymptomatic PML in natalizumab-treated MS patients","volume":"1","author":"Dong-Si","year":"2014","journal-title":"Ann. Clin. Transl. Neurol."},{"issue":"6","key":"10.1016\/j.jns.2017.03.001_bb0050","first-page":"637","article-title":"Predictors of survival and functional outcomes in natalizumab-associated progressive multifocal leukoencephalopathy","volume":"21","author":"Dong-Si","year":"2015","journal-title":"J. Neuro-Oncol."},{"issue":"10","key":"10.1016\/j.jns.2017.03.001_bb0055","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1177\/1352458514531843","article-title":"Does risk stratification decrease the risk of natalizumab-associated PML? Where is the evidence?","volume":"20","author":"Cutter","year":"2014","journal-title":"Mult. Scler."},{"issue":"3","key":"10.1016\/j.jns.2017.03.001_bb0060","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1002\/ana.24009","article-title":"Multiple sclerosis: prospects and promise","volume":"74","author":"Hauser","year":"2013","journal-title":"Ann. Neurol."},{"issue":"1\u20132","key":"10.1016\/j.jns.2017.03.001_bb0065","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.jns.2010.09.012","article-title":"Decisions on multiple sclerosis immunotherapy: new treatment complexities urge patient engagement","volume":"306","author":"Heesen","year":"2011","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.jns.2017.03.001_bb0070","article-title":"Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis","volume":"9","author":"Tramacere","year":"2015","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.jns.2017.03.001_bb0075","doi-asserted-by":"crossref","first-page":"197","DOI":"10.2147\/NDT.S17522","article-title":"When neurologist and patient disagree on reasonable risk: new challenges in prescribing for patients with multiple sclerosis","volume":"7","author":"Kachuck","year":"2011","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"10.1016\/j.jns.2017.03.001_bb0080","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1136\/bmj.314.7094.1580","article-title":"Doctors and patients don't agree: cross sectional study of patients' and doctors' perceptions and assessments of disability in multiple sclerosis","volume":"314","author":"Rothwell","year":"1997","journal-title":"BMJ"},{"issue":"12","key":"10.1016\/j.jns.2017.03.001_bb0085","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1177\/1352458510379819","article-title":"Risk perception in natalizumab-treated multiple sclerosis patients and their neurologists","volume":"16","author":"Heesen","year":"2010","journal-title":"Mult. Scler."},{"key":"10.1016\/j.jns.2017.03.001_bb0090","series-title":"Natalizumab (Natalizumab\u00ae) Summary of Product Characteristics","year":"2013"},{"key":"10.1016\/j.jns.2017.03.001_bb0095","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1212\/WNL.33.11.1444","article-title":"Rating neurological impairment in multiple sclerosis: an expanded disability status scale","volume":"33","author":"Kurtzke","year":"1983","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2017.03.001_bb0100","first-page":"83","article-title":"The symbol digit modalities test","volume":"3","author":"Smith","year":"1968","journal-title":"Learn. Disord."},{"issue":"3","key":"10.1016\/j.jns.2017.03.001_bb0105","first-page":"21","article-title":"The control preferences scale","volume":"Fall 29","author":"Degner","year":"1997","journal-title":"Can. J. Nurs. Res."},{"key":"10.1016\/j.jns.2017.03.001_bb0110","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1191\/1352458504ms1112oa","article-title":"Decisional role preferences, knowledge and information interests in patients with multiple sclerosis","volume":"10","author":"Heesen","year":"2004","journal-title":"Mult. Scler."},{"issue":"6","key":"10.1016\/j.jns.2017.03.001_bb0115","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1177\/1756285615602832","article-title":"Progressive multifocal leukoencephalopathy: current treatment options and future perspectives","volume":"8","author":"Pavlovic","year":"2015","journal-title":"Ther. Adv. Neurol. Disord."},{"issue":"8","key":"10.1016\/j.jns.2017.03.001_bb0120","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1177\/1352458512439238","article-title":"Natalizumab discontinuation after PML risk stratification: outcome from a shared and informed decision","volume":"18","author":"Tur","year":"2012","journal-title":"Mult. Scler."},{"issue":"12","key":"10.1016\/j.jns.2017.03.001_bb0125","doi-asserted-by":"crossref","first-page":"e82796","DOI":"10.1371\/journal.pone.0082796","article-title":"Risk acceptance in multiple sclerosis patients on natalizumab treatment","volume":"8","author":"Tur","year":"2013","journal-title":"PLoS One"},{"issue":"12","key":"10.1016\/j.jns.2017.03.001_bb0130","doi-asserted-by":"crossref","first-page":"e50718","DOI":"10.1371\/journal.pone.0050718","article-title":"Multiple sclerosis decreases explicit counterfactual processing and risk taking in decision making","volume":"7","author":"Simioni","year":"2012","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.jns.2017.03.001_bb0135","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.msard.2015.03.003","article-title":"Risk tolerance to MS therapies: survey results from the NARCOMS registry","volume":"4","author":"Fox","year":"2015","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"1\u20132","key":"10.1016\/j.jns.2017.03.001_bb0140","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.jns.2014.06.030","article-title":"Patient centered decision making: use of conjoint analysis to determine risk-benefit trade-offs for preference sensitive treatment choices","volume":"344","author":"Wilson","year":"2014","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.jns.2017.03.001_bb0145","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1111\/j.1539-6053.2008.00033.x","article-title":"Helping doctors and patients make sense of health statistics","volume":"8","author":"Gigerenzer","year":"2007","journal-title":"Psychol. Sci. Public Interest"}],"container-title":["Journal of the Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X17301624?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X17301624?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,17]],"date-time":"2020-05-17T17:27:35Z","timestamp":1589736455000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022510X17301624"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5]]},"references-count":28,"alternative-id":["S0022510X17301624"],"URL":"https:\/\/doi.org\/10.1016\/j.jns.2017.03.001","relation":{},"ISSN":["0022-510X"],"issn-type":[{"value":"0022-510X","type":"print"}],"subject":[],"published":{"date-parts":[[2017,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Benefit-risk perception of natalizumab therapy in neurologists and a large cohort of multiple sclerosis patients","name":"articletitle","label":"Article Title"},{"value":"Journal of the Neurological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jns.2017.03.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}